Introduction
Papillary carcinomas (PTC) are the most prevalent malignancies of the thyroid gland. In PTC, chromosomal inversions or translocations cause the recombination of the intracellular kinase-encoding domain of the RET receptor to heterologous genes, generating chimeric oncogenes designated RET/PTC (Jhiang, 2000; Pierotti, 2001) . RET/PTC1, the H4-RET fusion (Grieco et al., 1990) , and RET/PTC3, the RFG-RET fusion (Santoro et al., 1994a) , are the most prevalent variants. RET/PTC oncogenes are able to initiate thyroid carcinogenesis as shown by the fact that RET/ PTC-transgenic mice develop papillary thyroid carcinomas (Jhiang, 2000) . The observation that not all RET/ PTC-transgenics develop carcinomas suggests that secondary stochastic events are required for malignant progression. RET/PTC oncogenes are highly prevalent in clinically silent small papillary carcinomas (microcarcinomas) and in very small thyroid lesions with uncertain malignant potential, suggesting that they are early events in tumorigenesis and are not sufficient for the development of symptomatic thyroid cancers (Viglietto et al., 1995; Sugg et al., 1998; Corvi et al., 2001) .
In RET/PTC oncoproteins, the fusion with partners possessing protein-protein interaction motifs provides the RET kinase with a dimerizing interface. This results in constitutive dimerization and phosphorylation of the chimeric oncoproteins and in constant upregulation of RET signaling (Tong et al., 1997; Monaco et al., 2001) . RET signaling depends on tyrosine 1062, an autophosphorylation site positioned in its carboxy-terminal tail and, thus, retained in the RET/PTC oncoproteins. pY1062 is embedded in an NKLpY (single-letter amino-acid code) motif and mediates recruitment of various proteins (for a review see Manie et al., 2001 ) and references therein. Among them, Shc and FRS2 are recruited to RET pY1062 via their phosphotyrosine binding (PTB) domains (Mercalli et al., 2001; Melillo et al., 2001) ; by bridging RET-to-Grb2-Sos complexes, Shc and FRS2 play a key role in the activation of Ras small GTPases.
The effect of oncogenes in thyrocytes can be studied in various culture systems, including rat thyroid cell lines and primary cultures of rat, dog, sheep, and human thyroid. The different characteristics of these model cell systems have been recently reviewed (Kimura et al., 2001) . Although results obtained with cultured cells must be cautiously extrapolated to in vivo models, these different cell systems have been proven useful to study differentiation, survival, and growth regulation in an epithelial thyroid cell setting. PC CL 3, a continuous line of Fischer rat thyroid cells, constitutes one of the available thyrocyte models. PC CL 3 cells express differentiation markers and depend on a mixture of 6 hormones, including TSH and insulin, for proliferation (Fusco et al., 1987a) . We have previously shown that the expression of the RET/PTC1 oncogene causes hormoneindependent proliferation and abolishes differentiated gene expression of PC CL 3 cells (Santoro et al., 1993) . These data were in agreement with resistance to thyrotropin induced by other tyrosine kinases, such as the EGFR (Roger and Dumont, 1982) and the HGFR (Dremier et al., 1994) , in primary dog thyroid cells. Here we show that, in addition to these mitogenic and dedifferentiative effects, the RET/PTC1 and RET/PTC3 oncogenes induce apoptosis of PC CL 3 cells, and that this effect is dependent on RET/PTC enzymatic activity and pY1062-mediated triggering of the Ras signaling cascade, a process that in turn leads to an increased Bax to Bcl-2 ratio.
Results

RET/PTC1 and RET/PTC3 induce apoptosis of PC CL 3 cells
We cloned RET/PTC1 and RET/PTC3 cDNAs ( Figure 1a ) into a mammalian expression vector (pcDNA3) resistant to neomycin. PC CL 3 cells were transfected with RET/PTC I and RET/PTC3 as well as with the empty vector and selected for 2 weeks in neomycin containing medium. PC CL 3 cells transfected with the empty vector produced many large colonies, whereas RET/PTC I and three transfection resulted in a few small colonies (Figure 1b) . The number of colonies formed by RET/PTC-transfected cells was approximately ten times smaller with respect to colonies formed by empty-vector-transfected cells (see also Figure 3 ). To determine whether this reflected the cytotoxic effects of RET/PTC constructs due to apoptosis, neomycinresistant PC CL 3 colonies transfected with RET/PTC oncogenes or with the empty vector were pooled and expanded. Single clones were also isolated (three for each construct). The results obtained with isolated clones were identical to those obtained with mass population. Thus, results described thereafter are those obtained with mass populations. The expression of the Figure 2b , RET/PTC-transfected cells proliferated in complete medium more slowly than vector-transfected cells. Since the net rate of growth of a cell population results from the difference between proliferation and cell death, these findings could indicate that RET/PTC oncogenes induce thyrocyte apoptosis. Thus, flow cytometry was used to measure the percentage of apoptotic cells. Vector-, RET/PTC 1 and RET/PTC3 -transfected cells were plated overnight. Floating and adherent cells were collected 72 h later, fixed, stained with propidium iodine and processed for flow cytometry. The frequency of cells with hypodiploid DNA content was significantly higher among RET/PTC 1 and RET/PTC3 cells (2573 and 2073%) than among vector-transfected cells (572%) (Figure 2c ). Finally, internucleosomal DNA fragmentation was evaluated by the TUNEL assay in RET/PTC 1 and RET/PTC3-expressing cells. As a positive control, we used a potent apoptotic stimulus (2 ng/ml vincristme) (data not shown). Apoptosis was measured in five randomly selected microscopic fields. One representative microscopic field is reported in Figure 2d . Apoptotic nuclei were rare (o5%) in vector-transfected cells. Approximately, 20% of the nuclei of RET/PTC-oncogeneexpressing cells were apoptotic. Taken together, these results indicate that RET/PTC-oncogene-expressing PC CL 3 cells are more prone to perish by apoptosis than vector-transfected cells.
Tyrosine Y1062 mediates RET/PTC apoptotic effects
In addition to the autocatalytic tyrosine Y905 that is implicated in enzymatic function, full-length RET has five major phosphoiylation sites (Y687, Y826, Y1015, (Liu et al., 1996) . Because of the truncation, rearranged RET/PTC proteins maintain only four of these tyrosines and lack Y687. Phosphorylated Y1015 (pY1015) interacts with phospholipase Cg (PLCg) (Borrello et al., 1996) , whereas pY1062 is a docking site for the recruitment of multiple effectors (see Introduction). We constructed a panel of mutants in the RET/PTC1 background. These included a kinase-inactive RET/PTC1 (RET/PTC1 K-), carrying the substitution of the catalytic lysine (K758) to methionine, a RET/PTC1 mutant (RET/PTCI 4F) in which the four major autophosphorylation sites (Y826, Y1015, Y1029, and Y1062) were substituted by phenylalanines, and single mutants in Y1015 (Y10I5F) or Y1062 (Y10623F) (Figure 3a ). Each construct was transfected into HEK293 cells and analyzed with the aid of SDS gels and anti-RET antibodies: each transfection produced proteins of the appropriate mobility (not shown). PC CL 3 cells were transfected in triplicate with these constructs or the empty vector and selected in neomycin-containing medium for 2 weeks. Colonies were counted after the selection and the results are summarized in the bar-graphs of Figure 3b . Differently from wild-type RET/PTC1, the cytotoxic effects of the kinase-inactive mutant were barely detectable. RET/PTC-cytotoxicity depended on the integrity of the major phosphorylation sites because the 4F mutant lacked cytotoxic effects; in particular, Y1062, but not Y1015, was essential for cytotoxicity.
To verify whether apoptosis was directly because of RET/PTC signaling rather than being a secondary and late effect of thyroid cell transformation, we set up a transient assay in which cells were analyzed 60 h after transfection. RET/PTC1 and its kinase-inactive and Y1062F mutants, were transiently expressed in PC CL 3 cells together with trace amounts of EGFP to track transfected cells. Internucleosomal DNA fragmentation was evaluated by the TUNEL assay. Apoptosis was measured in five randomly selected microscopic fields; at least 100 EGFP-positive cells were counted. One representative microscopic field and the average results of three experiments are reported in Figure 4 . Apoptotic nuclei were rare (o5%) in vector-transfected cells. RET/PTC1 induced massive apoptosis. RET/PTCmediated apoptosis depended on its enzymatic activity and on phosphorylation of Y1062. In fact, the apoptotic rates of cells transfected with the kinase-dead and Y 1062F mutants were significantly lower than that induced by the wild-type construct. Still, the Y1062F mutant induced a modest apoptotic rate indicating that other signalling residues may contribute to RET/PTCinduced cell suicide (Figure 4 ).
Apoptosis of PC CL 3 cells is mediated by RET/PTC-dependent up regulation of the Ras/ERK signaling pathway
Ras activation is promoted by the coupling of phosphorylated Y1062 of RET with Grb2-Sos complexes via multiple docking proteins (for a review see Manie et al. (2001) and references therein). A key cellular response to Ras is transduced through the extracellular While Ras/ERK activation protects neuronal cells from apoptosis (Xia et al., 1995) , strong activation of this pathway has proapoptotic effects in other cell types (Kauffmann-Zeh et al., 1997) . Thus, we sought to determine whether Ras/ERK activation by RET/PTC Y1062 was essential for RET/PTC-mediated apoptosis. RET/PTC1 was transiently expressed in PC CL 3 cells together with trace amounts of EGFP with and without a five-fold excess of the dominant-interfering RasN17 mutant. At 48 h after transfection, cells not receiving RasN17 were treated with PD98059 (35 mm) or vehicle for an additional 12 h, and the apoptotic rate was evaluated by the TUNEL assay. RasN17 expression and treatment with PD98059 significantly reduced RET/ PTC1-induced apoptosis (Figure 5e ). Both treatments did not completely abrogate RET/PTC-mediated apoptosis. However, their effects were specific as we did not observe any protective effect exerted by RasN17 and by PD98059 on cell death induced by an apoptotic trigger other than RET/PTC (100 nglmt vincristine for 12 h) (Figure 5f ). Finally, in agreement with the toxic effects exerted by the Ras pathway in PC CL 3 cells, expression of constitutively active H-Ras (V12) had potent proapoptotic effects (Figure 5e ).
RET/PTC tyrosine 1062 mediates Bcl-2 down regulation and Bax up regulation in PC-RET=PTC cells Bcl-2 family proteins have emerged as fundamental regulators of the discharge of cytochrome C from mitochondria and, in turn, apoptosome formation during apoptosis. Bcl-2, Bcl-x L and Mcl-l are anti apoptotic proteins, and Bax, Bak, Bok and 'BH3-domain only' are proapoptotic proteins (Evan and Littlewood, 1998) . Activated proapoptotic Bax and Bak promote mitochondria permeabilization by forming a multimeric pore causing the initial efflux of cytochrome c. Antiapoptotic Bc1-2 proteins obstruct this process by sequestering 'BH3-domain only' molecules; thus preventing the allosteric activation of Bax. The ratio between antiapoptotic and proapoptotic Bcl-2 proteins ultimately determines cell susceptibility to apoptotic death (Evan and Littlewood, 1998) .
To gain insight into RET/PTC-mediated apoptosis, we investigated the expression levels of Bcl-2, Bcl-x L , decreased Bcl-2 levels, supporting the possibility that these proapoptotic expression changes are mediated by Ras (Figure 6a ). We performed real-time RT-PCR amplification to verify whether Bcl-.2 and Bax modulation occurred at mRNA level. Bcl-2 mRNA down regulation (>10 fold) was readily detected in RET/ PTC1-and v-Ha-Ras expressing cells, but not in cells expressing the Y1062F RET/PTC mutant. In the case of Bcl-2, changes were lower at mRNA level than at protein level. Bax mRNA levels were unchanged in transformed cells, pointing to a post-transcriptional level of regulation (Figure 6b ). To verify whether changes in the ratio of Bax to Bcl-2 proteins are a factor in the apoptosis of PC-RET/PTC cells, RET/PTC1 was transiently expressed in PC CL 3 cells with or without a three-fold excess of a Bcl-2 expression vector; transfected cells were tracked with trace amounts of EGFP. Apoptosis was evaluated by the TUNEL assay. Bcl-2 expression prevented RET/ PTC1-induced apoptosis (Figure 6c ).
Discussion
Here we show that the expression of RET/PTC oncogenes causes apoptosis of rat thyroid epithelial cells. Transient expression of RET/PTC induces apoptosis of a large fraction (B50%) of transfected PC CL 3 cells, whereas a lower fraction (B25%) undergo suicide upon stable expression of RET/PTC. These findings are consistent with a model in which acute RET/PTC signaling has proapoptotic effects; cells chronically exposed to RET/PTC signaling in vitro eventually undergo secondary changes that inactivate the apoptotic cascade and partially mitigate the apoptotic effects of RET/PTC.
RET/PTC-mediated apoptosis depends on RET/PTC's enzymatic activity and on the phosphorylation of the tyrosine residue corresponding to Y1062 in full-length RET. Intriguingly, in thyroid cells, tyrosine 1062 also mediates the loss of the differentiation markers and the ability to proliferate in the absence of six hormones . Thus, signals originating from a single tyrosine cause autonomous proliferation and de-differentiation of thyrocytes and are detrimental to cell survival. Activation of MAPK is a downstream event common to the triggering of different tyrosine kinases in thyroid cells (Lamy et al., 1993) . Tyrosine 1062 mediates sustained Ras/ERK activation by RET/PTC (this paper and Melillo et al., 2001) . We show that Ras/ERK is an important component of RET/PTC apoptotic signaling; indeed, PD98059, used at the minimally effective concentration verified to block kinase activation, and expression of a dominant negative Ras prevented cell death. Ras can promote both cell death and cell survival, depending on cell type, the nature of concomitant regulatory signals, and the effectors used. At least in some systems, Ras triggers apoptosis by activating Raf/ERK (Downward, 1998) . In addition to the data reported in the present paper, there is compelling evidence that Ras activation promotes apoptosis of thyroid cells. PC CL 3 thyroid cells undergo massive apoptosis consequent to acute activation of Ras and MEK 1 (Shirokawa et al., 2000) . H-Rasmediated apoptosis was shown to depend on concomitant activation of cyclic AMP (Shirokawa et al., 2000) . Cheng (Cheng and Meinkoth, 2001) reported that constitutive expression of oncogenic H-Ras sensitizes Wistar rat thyroid cells to apoptosis induced by loss of anchorage. In this system, upon detachment (and thus when integrin signaling is impaired) cell survival rather than cell death was found to be dependent on sustained MAPK activation. Although dependent on Ras, RET/ PTC-mediated apoptosis is not dependent on concomitant cAMP activation (Castellone MD, unpublished). Thus, although sustained Ras/ERK activation is in general proapoptotic for thyrocytes, it is likely that specific concomitant signals originating from various oncoproteins are able to modulate the cell's response to death-promoting effects in different growth conditions. Intriguingly, we have previously reported that coexpression of activated Ras promotes tumorigenesis of RET/ PTC1-expressing PC CL 3 cells (Santoro et al., 1993) . However, consistent with a proapoptotic role exerted by Ras signalling, Ras expression did not reduce the apoptotic rate of PC CL 3-RET/PTC cells (data not shown). Thus, it appears that Ras signalling can play a dual role: it is both necessary for the establishment of the transformed phenotype, and is detrimental for survival of RET/PTC-transformed thyrocytes.
We show that in RET/PTC-expressing PC CL 3 cells, Ras-mediated signaling is involved in the up regulation of the proapoptotic Bax and in the down regulation of the antiapoptotic Bcl-2 protein. Interestingly, such changes are likely because of different mechanisms: Bcl-2 is significantly downregulated at mRNA level, whereas Bax is modified only at a post-transcriptional level.
Cancer results from derangement of the critical balance between the rate of cell division and programmed cell death. Apoptosis induced by deregulated oncogenes must be forestalled for a tumor to become established. Whereas thyroid cancer is relatively infrequent, occult microcarcinomas or minimal lesions with uncertain malignant potential are very frequent in random autopsy screenings (up to 35.6%) suggesting that as yet unknown factor(s) inhibit tumor progression. These clinically silent thyroid tumors are very often RET/PTC-positive (Viglietto et al., 1995; Sugg et al., 1998; Corvi et al., 2001) . Our findings suggest that at least one of the factors that could limit the expansion of small tumors sustaining RET gene rearrangements is the proapoptotic activity of RET/PTC. During tumor progression, secondary events can be selected to suppress RET/PTC apoptosis and to promote the expansion of the neoplastic clones. For instance, secondary genetic changes causing overexpression Bcl-2 or activation of other cell survival pathways as overexpression of Akt or downmodulation of PTEN, both events reported to occur in thyroid cancer (Gimm, 2001) , can effectively contrast RET/PTC-proapoptotic effects in thyroid carcinomas.
Materials and methods
Plasmids and antibodies
All the RET constructs used in this study encode the short (RET-9) spliced form and were cloned in pCDNA3(Myc-His) (Invitrogen, Groningen, The Netherlands). RET/PTCI and RET/PTC3 constructs are described elsewhere (Melillo et al., 2001) . The point mutants were generated by site-directed mutagenesis using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA, USA). The mutations were confirmed by DNA sequencing. RET/PTC1 (K-) is a kinase-dead mutant, carrying the substitution of the catalytic lysine (residue 758 in full-length RET) with a methionine. The RET/PTC1 mutant carrying the substitution to phenylalanine of four tyrosines (Y826, Y1015, Y1029 and Y1062) is referred to as RET/ PTCI(4F). RET/PTC1(Y1015F) and RET/PTC1(Y1062F) are single mutants in residues 1015 or 1062. For simplicity, we number the residues of RET/PTC proteins according to the corresponding residues in unrearranged RET. The Bcl-2 expression vector (pBabe-Bcl-2) was a kind gift of R Maestro (Maestro et al., 1999) .
Polyclonal anti-RET antibodies were raised using the kinase domain of the protein (Santoro et al., 1994b) . Anti-phosphotyrosine antibodies (4G10) were from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Rabbit polyclonal anti-MAPK (#9101) and antiphospho-MAPK (#9102) antibodies were from New England Biolabs (Beverley, MA, USA). Bcl 2 (N-19, sc-492) and Bax (P-19, sc-526) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal antia-tubulin was from Sigma Chemical Co. (St Louis, MO, USA). Secondary antibodies were from Santa Cruz Biotechnology
Cell culture and transfections
Parental and transformed PC CL 3 cells were cultured in Coon's-modified Ham F12 medium supplemented with 5% calf serum and a mixture of thyrotropin (10 mU/ml), hydrocortisone (10 nm), insulin (10 mg/ml), apo-transferrin (5 mg/ml), somatostatin (10nglml) and glycyl-histidyl-lysine (10 ng/ml) (Sigma Chemical Co.) according to Fusco et al. (1987b) . For stable transfections, 5 Â 10 5 cells were plated 48 h before transfection in 60-mm tissue culture dishes. The medium was changed to Dulbecco's modified Eagle's medium (DMEM) (GIBCO) containing 5% calf serum and six hormones. After 3 h calcium phosphate DNA precipitates were incubated with the cells for 1 h. DNA precipitates were removed, and cells were washed with serum-free DMEM and incubated with 15% glycerol in N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES) -buffered saline for 2 mm. Finally, cells were washed with DMEM and incubated in Coon's modified F12 medium supplemented with 5% calf serum and the six hormones. For the colony formation assay, colonies were counted after 2 weeks of G418 (neomycin) selection. Transfected cells were fixed in 11% glutaraldehyde in PBS, rinsed in distilled water and stained with 0.1% crystal violet in 20% methanol for 15 min and photographed.
Flow cytometry
Cells were harvested when subconfluent, fixed in methanol for 1 h at À201C, rehydrated in PBS for 1 h at 41C, and then treated with RNase A (100 U/ml) for 30 min. Propidium iodide (25 mg/ml) was added to the cells, and samples were analyzed with a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) interfaced with a Hewlett-Packard computer (Palo Alto, CA, USA).
TUNEL assay
Terminal desoxynucleotidyl transferase (TdT)-mediated desoxyuridine triphosphate (dUTP) nick end-labeling (TUNEL) was performed on stably or transiently transfected cells with the in situ Cell Death Detection Kit, from Roche Molecular Diagnostics (Basel, Switzerland) according to the manufacturer's instructions. For transient transfections, cells were transfected as indicated above. Transfected cells were identified with trace amounts (0.5 mg) of the plasmid encoding enhanced Green Fluorescent Protein (pEGFP, Clontech Laboratories, Palo Alto, CA, USA). After transfection (8 h later), an equal number (5 Â 10 3 ) of cells from the different lines was seeded onto 24-well plates (Costar Corp., Corning Incorporated, NY, USA) containing 1.4 cm 2 glass coverslips. Cells were fixed in a freshly prepared solution of 2% (w/v) paraformaldehyde in PBS pH 7.4 for 60 min at room temperature and permeabilized by soaking the coverslips for 2 min on ice in Hepes-Triton X-100 buffer (20 mm Hepes pH 7.4, 300 mm sucrose, 50 mm NaC1, 3 mm MgC1 2 and 0.5% Triton X-100). Coverslips were rinsed twice with PBS, airdried and subjected to the TUNEL reaction. All coverslips were counterstained in PBS containing Hoechst 33258 (final concentration, 1 mg/ml; Sigma Chemical Co.), rinsed in water and mounted in a 50% glycerol solution in PBS. The fluorescent signal, emitted by the red fluorescent tetramethyl rhodamine (TMR)-labeled dUTP incorporated into fragmented DNA, was visualized with an epifluorescent microscope (Axiovert 2, Zeiss) (equipped with a 100x lens) interfaced with the image analyzer software KS300 (Zeiss).
Protein studies
Protein extractions and Western blot were performed according to standard procedures. Protein concentration was estimated by a modified Bradford assay (Bio-Rad, Munich, Germany). Immune complexes were detected with the enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Little Chalfort, UK). For the ERK immunocomplex kinase assay, protein lysates (500 mg) were incubated with 2 ml of the specific antibody for 1 h at 41C, immunocomplexes were recovered with protein A-Sepharose (Amersham Pharmacia Biotech). Precipitates were washed six times in lysis buffer and incubated with 20 mg of myelin basic protein as a substrate. Intensifying screens were used for autoradiography. Signal intensity was analyzed at the Phosphorimager (Typhoon 8600, Amersham Pharmacia Biotech) interfaced with the ImageQuant software. Ras activation was measured by the Ras activation assay kit from Upstate Biotechnology Inc., according to the manufacturer's instructions. Briefly, cells were harvested when subconfluent and cell lysates were pre cleared with glutathione-agarose. GTP-bound Ras levels (1 mg of protein lysate) were determined by affinity precipitation (2 h at +41C with gentle rocking) with immobilized (10 ml gel slurry) Raf-1 RBD (Ras binding domain). Raf-1 RBD-bound Ras levels were determined by immunoblot with an anti-panisoform-specific Ras monoclonal antibody (clone RAS10).
Real-time quantitative PCR
Total RNA was isolated by using the RNAeasy mini kit (Quiagen, Hilden, Germany) and was cleaned with RNase-free DNAse (Quiagen). Random-primed first strand cDNA was synthesized in a 50 ml reaction volume starting from 2 mg RNA by using the Gene Amp RNA PCR Core Kit (Applied Biosystems, Warrington, UK). The quantitative PCR reaction was performed by using the SYBR Green PCR Master mix (Applied Biosystems) in an iCycler apparatus (BioRad). Amplification reactions (25 ml final reaction volume) contained 200 nm of each primer, 3 mm MgCl 2 300 mm dNTPs, 1x SYBRGreen PCR buffer, 0.1 U/ml A AmpliTaq Gold DNA Polymerase, 0.01 U/ml Amp Erase, RNase-free water and 2 ml cDNA samples. The thermal cycling conditions consisted of an initial cycle of 2 min at 501C; a cycle of 10 min at 951C and 40 cycles of 15 s of denaturation (951C) followed by 1 min of annealing/extension (601C). To verify the absence of non specific products, 80 cycles of melting (551C for 10 s) were performed. In all cases, the melting curve confirmed that a single product was generated. Real-time amplification was monitored by measuring the increase in fluorescence caused by the SYBR-Green binding to double-stranded DNA. b actin amplification was used for normalization. Fluorescent threshold values were measured in triplicate and fold changes were calculated by the formula: 2 À(sample 1 DCtÀsample 2 DCt)
, where DCt is the difference between the amplification fluorescent thresholds of the mRNA of interest and the b actin mRNA. Primers were designed by using softwares available at the following web addresses: http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi; http://www.operon.com/oligos/toolkit.php? Primers sequences were as follows: b actin forward: 5 0 -GTCAGGCAGCTCATAGCTCT-3 0 ; b actin reverse: 5 0 -TCGTGCGTGACATTAAAGAG-3 0 . Bcl-2 forward: 5 0 -GATCCAGGATAACGGAGGCT-3 0 ; BcI-2 reverse: 5 0 -CTGAGCAGCGTCTTCAGAGA-3 0 ; Bax forward: 5 0 -CGAGCTGATCAGAACCATCA-3 0 ; Bax reverse: 5'-GGTCCCGAAGTAGGAGAGGA-3 0 .
